Granules Pharma clears USFDA audit

The USFDA has issued two minor observations during the audit.

Picture: Pixabay

Last Updated on July 24, 2021 by The Health Master

Granules India yesterday announced that Granules Pharmaceuticals, a wholly-owned foreign subsidiary of the company located in Chantilly, Virginia, USA, has cleared a pre-approval inspection (PAI) for three of its applications filed from this facility.

The company, had undergone the PAI audit by the US Food and Drug Administration (USFDA) from 21st June, 2021 to 25th June, 2021. The USFDA has issued two minor observations during the audit.

Speaking in this regard, Priyanka Chigurupati, Executive Director, GPI, said, “The observations were responded to within the stipulated time, and we are happy to inform that the USFDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th July, 2021.

This is the fifth USFDA audit for this facility.”

Zydus Cadila gets USFDA nod for Ibrutinib tablets

Lupin gets USFDA nod for generic Antifungal drug

Unichem gets tentative USFDA nod for drug to treat Diabetes

Alembic gets USFDA final nod for Erlotinib Tablets

Alembic gets USFDA nod for drug for the treatment of Depression

USFDA approves Abbott’s Stent to treat high bleeding risk patients

Procedure to obtain license for manufacturing of drugs

Procedure to obtain License to Manufacture drugs for testing and analysis purposes

NPPA fixes retail prices of 14 formulations

High Court asks petitioner to move Drugs Inspector

APIs: Active Raw Materials for these Drugs get costlier by 139%

India and Pharmacy Education: Chapter:1

Subscribe for daily free updates


Enter your email address:

Delivered by FeedBurner